

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA ipilimumab for previously untreated advanced
(unresectable or metastatic) melanoma**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

No equality issues were raised during the scoping process.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

No equality issues have been raised in the submissions, expert statements or academic reports.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No equality issues were identified by the Committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for

the specific group?
No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
Yes, in the summary table in the ACD.

Approved by Associate Director (name): Janet Robertson.....

Date: 17/02/14

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?
--

Patient experts and a patient group raised a potential equality issue that patients with ocular melanoma being excluded from the preliminary recommendation of 'only in the context of research' since these patients are usually excluded from clinical trials. However the final guidance includes patients with cutaneous and ocular melanoma .

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

N/A

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

N/A

Approved by Centre or Programme Director (name): Meindert
Boysen.....

Date: 22/05/14